Kohji Takemura, MD· @KohjiToncol · X·· 2 天前评分70
正文 · 原文
TROPHY-U-01 Cohort 7: SG + EV + zimberelimab demonstrated promising efficacy (ORR 81%, n=21).
Looking forward to results from larger phase II/III trials!
#ESMO26
53 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
4742O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：Kohji Takemura, MD · x.com